IRB #

STUDY00020361

Title

Clinical Effectiveness of Conventional Versus Mirasol-treated
Apheresis Platelets in Patients with Hypoproliferative
Thrombocytopenia (MIPLATE)

Principal Investigator

Trisha Wong

Study Purpose

The purpose of this study is to learn about the safety and effectiveness of Mirasol Pathogen Reduction Technology System for Platelets. We are hoping to find out if the platelets treated with Mirasol PRT system works the same at preventing and controlling bleeding than platelets as the standard platelet transfusion.

Medical Condition(s)

Hypoproliferative Thrombocytopenia
Hematologic Malignancies

Eligibility Criteria

- Greater than 22lbs in weight
- Diagnosis of a hematologic malignancy with hypoproliferative thrombocytopenia
- No treatment with pathogen-reduced blood products in the past 6 months

Age Range

12 - 120

Healthy Volunteers Needed

No

Duration of Participation

up to 81 days.

Minors Included

Yes

Contact

Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)­494-­1080 or trials@ohsu.edu

Sponsor

Terumo BCT Biotechnologies

Recruitment End

01/01/2025

Compensation Provided

No


Go Back